GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRhythm Technologies Inc (NAS:IRTC) » Definitions » Debt-to-EBITDA

IRTC (iRhythm Technologies) Debt-to-EBITDA : -8.78 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is iRhythm Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

iRhythm Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $16.1 Mil. iRhythm Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $719.4 Mil. iRhythm Technologies's annualized EBITDA for the quarter that ended in Mar. 2025 was $-83.8 Mil. iRhythm Technologies's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was -8.78.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for iRhythm Technologies's Debt-to-EBITDA or its related term are showing as below:

IRTC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.54   Med: -1.43   Max: -0.78
Current: -12.54

During the past 11 years, the highest Debt-to-EBITDA Ratio of iRhythm Technologies was -0.78. The lowest was -12.54. And the median was -1.43.

IRTC's Debt-to-EBITDA is ranked worse than
100% of 456 companies
in the Medical Devices & Instruments industry
Industry Median: 1.445 vs IRTC: -12.54

iRhythm Technologies Debt-to-EBITDA Historical Data

The historical data trend for iRhythm Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRhythm Technologies Debt-to-EBITDA Chart

iRhythm Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.20 -1.41 -1.42 -1.34 -9.94

iRhythm Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.06 -18.05 -5.07 21.07 -8.78

Competitive Comparison of iRhythm Technologies's Debt-to-EBITDA

For the Medical Devices subindustry, iRhythm Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRhythm Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where iRhythm Technologies's Debt-to-EBITDA falls into.


;
;

iRhythm Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

iRhythm Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(15.867 + 721.042) / -74.126
=-9.94

iRhythm Technologies's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(16.14 + 719.362) / -83.808
=-8.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


iRhythm Technologies  (NAS:IRTC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


iRhythm Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of iRhythm Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


iRhythm Technologies Business Description

Traded in Other Exchanges
Address
699 8th Street, Suite 600, San Francisco, CA, USA, 94103
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Executives
Daniel G. Wilson officer: EVP, Strategy Corp Dev Inv Rel 699 8TH STREET, SUITE 600, SAN FRANCISCO CA 94103
Chad Patterson officer: Chief Commercial Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Minang Turakhia officer: EVP, CMO & CSO C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Quentin S. Blackford director, officer: President and CEO 7475 LUSK BLVD., SAN DIEGO CA 92121
Patrick Michael Murphy officer: CLO & EVP RA/QA MrktAcs & Gov 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Sumi Shrishrimal officer: EVP, Chief Risk Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Abhijit Y Talwalkar director ONE AMD PLACE, PO BOX 3453, SUNNYVALE CA 94088
Brice Bobzien officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Mervin Smith officer: EVP Strategic Business Ops C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Marc W. Rosenbaum officer: Chief Accounting Officer 7475 LUSK BLVD., SAN DIEGO CA 92121
Mark J. Day officer: EVP, Research & Development C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Brian B Yoor director 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064
Mojdeh Poul director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST PAUL MN 55144-1000
Douglas Devine officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH STREET, SUITE 600, SAN FRANCISCO CA 94103
Bairey Merz Cathleen Noel director 16664 CUMBRE VERDE COURT, PACIFIC PALISADES CA 90272